SCHEMBL299178

SCHEMBL299178

CC(C)(C)OC(=O)NC1=N[C@](C)(c2cccc([N+](=O)[O-])c2)CC(=O)N1Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ALOX5 P09917 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
REN P00797 1/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
P2RX7 Q99572 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
NPY1R P25929 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299179 1.00 MAPT (0.40) MAPTL3MBTL1TDP1LMNAALDH1A1
SCHEMBL298566 0.91 MAPT (0.43) MAPTL3MBTL1LMNAALDH1A1SMN1; SMN2
SCHEMBL298567 0.91 MAPT (0.43) MAPTL3MBTL1LMNAALDH1A1SMN1; SMN2
SCHEMBL287423 0.87 BACE1 (0.42) L3MBTL1ALDH1A1RENCTSDBACE1
SCHEMBL287424 0.87 BACE1 (0.42) L3MBTL1ALDH1A1RENCTSDBACE1
SCHEMBL568706 0.87 MAPT (0.40) MAPTLMNAALDH1A1SMN1; SMN2ALOX5
SCHEMBL299253 0.85 MAPT (0.45) MAPTLMNASMN1; SMN2ALOX5NPC1
SCHEMBL299252 0.85 MAPT (0.45) MAPTLMNASMN1; SMN2ALOX5NPC1
SCHEMBL287405 0.77 BACE1 (0.40) RENCTSDBACE1
SCHEMBL287406 0.77 BACE1 (0.40) RENCTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461160-B2 Dihydropyrimidinones HOFFMANN-LA ROCHE, INC. (US) 2013-06-11 US disclosed
EP-2427437-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 MAPT 143/4885L3MBTL1 4566/4885TDP1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.